Description

LS-BF1 is a stable and low toxic cationic antimicrobial peptide. LS-BF1 displays broad spectrum of antibacterial activity, including the challenging ESKAPE pathogens, by cell membrane disruptive mechanism. LS-BF1 shows good in vivo efficacy for elimination of bacteria in a mouse infection model[1].—COVID-19-immunoregulation–C107H166N28O15—-[1]Hu Y, et al. Lysine Stapling Screening Provides Stable and Low Toxic Cationic Antimicrobial Peptides Combating Multidrug-Resistant Bacteria In Vitro and In Vivo. J Med Chem. 2022;65(1):579-591. –2892148-58-0–2084.64—-O=C(N[C@@H](CCCCN)C(N[C@@H](CCCNC(N)=N)C(N[C@@H](CC1=CC=CC=C1)C(N[C@@H](CCCCN)C(N[C@@H](CCCCNC/C=C/CNCCCC[C@@H](C(N[C@@H](CC2=CC=CC=C2)C(N[C@@H](CCCCN)C(N[C@@H](CCCCN)C(N[C@@H](CC3=CC=CC=C3)C(N[C@@H](C(C)C)C(N)=O)=O)=O)=O)=O)=O)NC4=O)C(N[C@@H](CC5=CC=CC=C5)C(N[C@@H](CC6=CC=CC=C6)C(N[C@H]4CCCNC(N)=N)=O)=O)=O)=O)=O)=O)=O)[C@H](C(C)C)N–Infection–10 mM in DMSO–Bacterial—-Anti-infection–Peptides